Holen Sie sich die Stockscreener-App
9.70
0.73%
0.07
Handel nachbörslich:
9.70
Delcath Systems Inc Aktie (DCTH) Neueste Nachrichten
Delcath Systems (DCTH) Gains Recognition in Clinical Guidelines - gurufocus.com
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma - BioSpace
Delcath therapy included in European uveal melanoma guidelines By Investing.com - Investing.com India
Aug Levels: Is Delcath Systems Inc a strong candidate for buy and holdShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
EBIT per share of Delcath Systems, Inc. – MUN:DV3R - TradingView
DCTH PE Ratio & Valuation, Is DCTH Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - gurufocus.com
DV3R.SG,0P0000X679,0 (DV3R.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 earnings call transcript - MSN
Responsive Playbooks and the DCTH Inflection - Stock Traders Daily
Delcath Systems Inc. (US24661P8077.SG) Balance Sheet - Yahoo! Finance Canada
Delcath (NASDAQ: DCTH) seeks approval to expand 2020 equity incentive plan - Stock Titan
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting - BioSpace
Delcath Systems (DCTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Decliners Report: What are the future prospects of Delcath Systems IncProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Are options traders betting on a big move in Delcath Systems stock? - MSN
Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030 - GlobeNewswire
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Risk Analysis: Is Delcath Systems Inc backed by strong institutional buyingForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Market Catalysts: What is BDSXs 5 year growth outlookTrade Analysis Report & Safe Entry Zone Tips - baoquankhu1.vn
Understanding the Setup: (DCTH) and Scalable Risk - Stock Traders Daily
FRA:DV3R PB Ratio: 2.85 — 49% Below Median - GuruFocus
Form 13G DELCATH SYSTEMS For: 20 March By Investing.com - Investing.com Australia
Daniel Kaufman reports 5.08% stake in Delcath Systems (DCTH) - Stock Titan
Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH - MarketBeat
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail
Delcath Systems Q3 2025 Earnings Preview - MSN
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Delcath Systems (DCTH) CFO purchases 5,533 common shares at $9.04 - Stock Titan
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):